CARLSBAD, Calif., Nov. 4, 2015 /PRNewswire/ -- Isis
Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will
host a live webcast on Sunday, November
8 at 1:00 p.m. Eastern Time to
review ISIS-APO(a)Rx and
ISIS-APO(a)-LRx data presented at the
American Heart Association Scientific Sessions.
Interested parties may listen to the call by dialing
877-443-5662 or access the webcast at www.isispharm.com. A
webcast replay will be available for a limited time at the same
address.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is
the leading company in RNA-targeted drug discovery and development
focused on developing drugs for patients who have the highest unmet
medical needs, such as those patients with severe and rare
diseases. Using its proprietary antisense technology, Isis
has created a large pipeline of first-in-class or best-in-class
drugs, with over a dozen drugs in mid- to late-stage
development. Drugs currently in Phase 3 development include
volanesorsen, a drug Isis is developing and plans to commercialize
through its wholly owned subsidiary, Akcea Therapeutics, to treat
patients with familial chylomicronemia syndrome and familial
partial lipodystrophy; ISIS-TTRRx, a drug Isis is
developing with GSK to treat patients with all forms of TTR
amyloidosis; and ISIS-SMNRx, a drug Isis is developing
with Biogen to treat infants and children with spinal muscular
atrophy. Isis' patents provide strong and extensive
protection for its drugs and technology. Additional
information about Isis is available at www.isispharm.com.
ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding
Isis Pharmaceuticals' financial position and outlook, Isis'
business, and the therapeutic and commercial potential of Isis'
technologies and products in development. Any statement
describing Isis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such
statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering,
developing and commercializing drugs that are safe and effective
for use as human therapeutics, and in the endeavor of building a
business around such drugs. Isis' forward-looking statements
also involve assumptions that, if they never materialize or prove
correct, could cause its results to differ materially from those
expressed or implied by such forward-looking statements.
Although Isis' forward-looking statements reflect the good faith
judgment of its management, these statements are based only on
facts and factors currently known by Isis. As a result, you
are cautioned not to rely on these forward-looking
statements. These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form
10-K for the year ended December 31,
2014, and its most recent quarterly report on Form 10-Q,
which are on file with the SEC. Copies of these and other
documents are available from the Company.
Isis Pharmaceuticals® is a registered trademark of
Isis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark
of Isis Pharmaceuticals, Inc.
Logo -
http://photos.prnewswire.com/prnh/20130807/LA60006LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/isis-pharmaceuticals-to-host-webcast-to-review-isis-apoa-rx-and-isis-apoa-l-rx-data-presented-at-american-heart-association-scientific-sessions-300171799.html
SOURCE Isis Pharmaceuticals, Inc.